Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CB-012 in Relapsed/Refractory Acute Myeloid Leukemia
NCT06128044Phase 1Terminated
- Sponsor
- Caribou Biosciences
- Start
- Feb 2024
- Primary completion
- May 2025
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of CB-012 in acute myeloid leukemia (AML) (2 arms), sponsored by Caribou Biosciences. Primary endpoints: Dose Limiting Toxicities at 28 days and Overall Response Rate at 12 months. Started Feb 2024; status: terminated.
02
Drugs
CB-012
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT06128044.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06128044.